Repeated anti-CEA-radioimmunotherapy (RAIT) with 131iodine-labetuzumab after resection of colorectal liver metastases (CLM): a prospective phase II study.
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2015
At a glance
- Drugs Labetuzumab I 131 (Primary)
- Indications Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- Sponsors Immunomedics
- 25 Jun 2007 New trial record.